Evidence map›Paper›PMID 34036737›Full record

ReviewThe FEBS journal2022

Cancer cell metabolism connects epigenetic modifications to transcriptional regulation.

Ashby J Morrison

Open access · bronzeAbstract readReview
In one paragraph

Review in The FEBS journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. The metabolic profiles of cancer stem cells.Stem cell research & therapy · 2026
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Ashby J MorrisonDepartment of Biology, Stanford University, Stanford, CA, USA.ORCID 0000-0003-1228-5093
Stanford University · US

Funding

The Role of Chromatin in Metabolic Homeostasis SupplementalR35GM119580 · NIGMS · STANFORD UNIVERSITY · PI MORRISON, ASHBY J. · 2016 to 2025
$4.7M
NIGMS NIH HHS R35 GM119580
6 · The paper itself

Abstract

Adaptation of cellular function with the nutrient environment is essential for survival. Failure to adapt can lead to cell death and/or disease. Indeed, energy metabolism alterations are a major contributing factor for many pathologies, including cancer, cardiovascular disease, and diabetes. In particular, a primary characteristic of cancer cells is altered metabolism that promotes survival and proliferation even in the presence of limited nutrients. Interestingly, recent studies demonstrate that metabolic pathways produce intermediary metabolites that directly influence epigenetic modifications in the genome. Emerging evidence demonstrates that metabolic processes in cancer cells fuel malignant growth, in part, through epigenetic regulation of gene expression programs important for proliferation and adaptive survival. In this review, recent progress toward understanding the relationship of cancer cell metabolism, epigenetic modification, and transcriptional regulation will be discussed. Specifically, the need for adaptive cell metabolism and its modulation in cancer cells will be introduced. Current knowledge on the emerging field of metabolite production and epigenetic modification will also be reviewed. Alterations of DNA (de)methylation, histone modifications, such as (de)methylation and (de)acylation, as well as chromatin remodeling, will be discussed in the context of cancer cell metabolism. Finally, how these epigenetic alterations contribute to cancer cell phenotypes will be summarized. Collectively, these studies reveal that both metabolic and epigenetic pathways in cancer cells are closely linked, representing multiple opportunities to therapeutically target the unique features of malignant growth.

Indexed as

Epigenesis, GeneticTranscription, GeneticAntineoplastic AgentsCarcinogenesisCell ProliferationChromatinGene Expression Regulation, NeoplasticGene Regulatory NetworksHistonesHumansMetabolic Networks and PathwaysMolecular Targeted TherapyNeoplasm ProteinsNeoplasmsSignal TransductionTranscription FactorsAntineoplastic AgentsChromatinHistonesNeoplasm ProteinsTranscription FactorsacetylationacylationcancerDNA methylationglycolysishistonemetabolismmethylationoxidative phosphorylation

Identifiers

PMID34036737
PMCPMC8613311
OpenAlexW3164848310

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.